Hirofumi Nakano

ORCID: 0000-0003-4481-237X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lymphoma Diagnosis and Treatment
  • Organ Transplantation Techniques and Outcomes
  • Liver Disease and Transplantation
  • Immune Cell Function and Interaction
  • Viral-associated cancers and disorders
  • Cancer Mechanisms and Therapy
  • Acute Myeloid Leukemia Research
  • Blood Pressure and Hypertension Studies
  • Renal Diseases and Glomerulopathies
  • Pancreatic function and diabetes
  • Central Venous Catheters and Hemodialysis
  • Neutropenia and Cancer Infections
  • CNS Lymphoma Diagnosis and Treatment
  • Hematopoietic Stem Cell Transplantation
  • Drug-Induced Hepatotoxicity and Protection
  • Chronic Lymphocytic Leukemia Research
  • Dialysis and Renal Disease Management
  • Blood Coagulation and Thrombosis Mechanisms
  • Pleural and Pulmonary Diseases
  • Liver Disease Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations
  • Liver physiology and pathology
  • Organ and Tissue Transplantation Research
  • Kawasaki Disease and Coronary Complications
  • Gastric Cancer Management and Outcomes

Jichi Medical University
2014-2022

The University of Tokyo
2012-2020

Jichi Medical University Hospital
2018

Jichi Medical University Saitama Medical Center
2014

St. Marianna University School of Medicine
2013

ENT and Allergy
2013

The Open University of Japan
2012

Fuchu Hospital
2012

Nagasaki University
1999-2010

Toshima Hospital
2008

Abstract Tumor-associated macrophages affect tumor progression and resistance to immune checkpoint therapy. Here, we identify the chemokine signal regulator FROUNT as a target control tumor-associated macrophages. The low level expression in patients with cancer correlates better clinical outcomes. Frount -deficiency markedly reduces decreases macrophage tumor-promoting activity. is highly expressed macrophages, its myeloid-specific deletion impairs growth. Further, anti-alcoholism drug...

10.1038/s41467-020-14338-5 article EN cc-by Nature Communications 2020-01-30

Serine/threonine kinase PIM1 is an emerging therapeutic target for hematopoietic and prostate cancer therapy. To develop a novel inhibitor, we focused on 1, metabolically labile, nonselective inhibitor discovered in our previous screening study. We adopted rational optimization strategy based mainly structural information the PIM1-1 complex to improve potency selectivity. This approach afforded potent stable PIM1-selective 14, which shows only marginal increase molecular weight compared with...

10.1021/jm3001289 article EN Journal of Medicinal Chemistry 2012-04-27

Significant activity changes due to small structural (i.e., cliffs) of serine/threonine kinase Pim1 inhibitors were studied theoretically using the fragment molecular orbital method with mechanics Poisson–Boltzmann surface area (FMO+MM-PBSA) approach. This methodology enables quantum-chemical calculations for large biomolecules solvation. In course drug discovery targeting Pim1, six benzofuranone-class found differ only in position indole-ring nitrogen atom. By comparing various qualities...

10.1021/acs.jcim.7b00110 article EN Journal of Chemical Information and Modeling 2017-11-07

Accelerated matrix breakdown caused by the increased activity of metalloproteinases (MMPs) and/or quantitative imbalance between MMP and tissue inhibitor (TIMP) have been implicated in several pathological conditions. TIMP may also be involved destruction coronary arterial wall resultant lesions Kawasaki disease.Plasma levels MMPs, neutrophil elastase, TIMPs were measured enzyme-linked immunoassay 57 patients with disease no (group 1) 8 2). Blood samples obtained before after intravenous...

10.1161/hc3301.095286 article EN Circulation 2001-08-21

Abstract Recent studies have revealed unique biological characteristics of molecular hydrogen (H 2 ) as an anti-inflammatory agent. We developed a novel haemodialysis (E-HD) system delivering H (30–80 ppb)-enriched dialysis solution by water electrolysis, and conducted non-randomized, non-blinded, prospective observational study exploring its clinical impact. Prevalent chronic HD patients were allocated to either the E-HD (n = 161) group or conventional (C-HD: n 148) group, received...

10.1038/s41598-017-18537-x article EN cc-by Scientific Reports 2018-01-04

The application of electrolyzed water (EW) at the cathode side to manufacture reverse osmosis (RO) and hemodialysis (HD) solution can actually lead less oxidative capacity in chemical terms. present study examined biological actions this on human polymorphonuclear leukocytes (PMNs), clinical feasibility applying technology HD treatment.RO using EW (e-RO) exhibited chemiluminescence luminol-hydrogen peroxide higher dissolved hydrogen levels (-99.0 ppb) compared with control RO water. effects...

10.1159/000210569 article EN Nephron Clinical Practice 2009-04-02

In the development of kinase inhibitors, one major concerns is selectivity. An effective strategy to achieve high selectivity utilize structural differences among kinases inform inhibitor design. Here, we set out improve PIM (proviral integration site for Moloney murine leukemia virus) kinase-inhibitory our previously reported 7-azaindole derivative 2, which has promising ADMET properties, by targeting a unique bulge in ATP-binding pocket. 6-Substituted 7-azaindoles, especially 6-chlorinated...

10.1021/acsmedchemlett.6b00518 article EN ACS Medicinal Chemistry Letters 2017-04-03

Protein kinases are attractive targets for both biological research and drug development. Several assay kits, especially the detection of adenosine diphosphate (ADP), which is universally produced by kinases, commercially available high-throughput screening (HTS) kinase inhibitors, but their cost quite high large-scale screening. Here, we report a new enzyme-coupled fluorescence ADP detection, uses just 10 inexpensive, components. The protocol very simple, requiring only mixing test...

10.1177/2472555218810139 article EN cc-by-nc-nd SLAS DISCOVERY 2018-11-12

Previous studies have shown that most patients lose immunity to measles, mumps, and rubella (MMR) during long-term follow-up after allogeneic hematopoietic stem cell transplantation (HSCT), immunizations against them been investigated. However, these previous mainly targeted pediatric information in adult is still insufficient.

10.1179/1607845414y.0000000174 article EN Hematology 2014-07-03

We evaluated 121 patients with follicular lymphoma (FL) and analyzed the association between soluble interleukin-2 receptor (sIL-2R) level at diagnosis cumulative incidence of transformation. By a receiver-operating characteristic analysis, we determined cutoff value sIL-2R for transformation 4360 U/mL to classify into two groups. Patients in high group showed shorter progression-free survival (PFS) disease-specific (DSS) (p < 0.001 p = 0.018). Furthermore, was higher than that low (40.9%...

10.1080/10428194.2016.1190975 article EN Leukemia & lymphoma/Leukemia and lymphoma 2016-06-07

The preparation of three new types phenylboronic acid derivatives and their evaluation as enhancers on the luminol-H(2)O(2)-horseradish peroxidase (HRP) chemiluminescence (CL) reaction are described. After optimizing CL conditions, system was applied to HRP determination. Among derivatives, i.e. 4-(4, 5-diphenyl-1H-imidazol-2-yl)phenylboronic (DPA), 4-[4(or 5)-(4-dimethylaminophenyl)-5(or 4)-phenyl-1H-imidazol-2-yl]phenylboronic (DAPA) 4-[4, 5-di(2-pyridyl)-1H-imidazol-2-yl]phenylboronic...

10.1002/(sici)1522-7243(199911/12)14:6<361::aid-bio563>3.0.co;2-j article EN Luminescence 1999-11-01

Follicular lymphoma (FL) is a clinically and biologically heterogeneous disease. Therefore, it important to identify factors that can predict its clinical outcome.We retrospectively evaluated the usefulness of soluble interleukin-2 receptor (sIL-2R) levels after R-CHOP (posttreatment sIL-2R) in 72 patients with newly diagnosed FL who had either complete response (CR) or partial response. With use recursive partitioning analysis, we determined cut-off values post- pretreatment sIL-2R were...

10.1080/10245332.2017.1312204 article EN Hematology 2017-04-17

Elderly patients with non-Hodgkin lymphoma (NHL) have a poor prognosis. Owing to treatment-related toxicities, there is no standard chemotherapy for the elderly patients, especially those aged 70 years or older. In this study, we retrospectively evaluated efficacy and toxicity of reduced-dose (two-thirds) R-CHOP as an initial 45 older B-cell NHL. The WHO classification NHL included diffuse large (DLBCL) (31), mantle cell (5), follicular (4), extranodal marginal zone (1), Burkitt whose...

10.1179/1973947814y.0000000219 article EN Journal of Chemotherapy 2014-10-14
Coming Soon ...